|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Membrane surfaces immobilized with ionic or reduced silver and their anti-biofouling performances显示文摘 | Xiaoying Zhu Renbi Bai Kin-Ho Wee Changkun Liu Shu-Ling Tang | 2010 | Journal of Membrane Science2010，，1： | 1 |
| 2 | “Galaxy Serpent”Second Version National Nuclear Forensic Library Virtual Tabletop Exercise显示文摘'Galaxy Serpent'Second Version(GSv2)National Nuclear Forensic Library Virtual Tabletop Exercise which was based on internet concerning the application of sealed radioactive sources database was organized by nuclear forensic international technical working group(ITWG).There are three phases in GSv2:De- | WANG Fan LIU Guorong ZHAO Yonggang WANG Tongxing LI Lili ZHU Liuchao ZHOU Hao ZHANG Yan XU Changkun LI Jianhua JIANG Xiaoyan | 2017 | Annual Report of China Institute of Atomic Energy2017，，1： | 0 |
| 3 | Uranium Isotope Ratio Analysis of Uranium Pellet显示文摘The analysis of uranium isotope ratio in uranium pellets is an important content of nuclear forensics.Thermal ionization mass spectrometry(TIMS)and multi-collector inductively coupled plasma mass spectrometry(MC-ICPMS)are high precision isotope ratio analysis methods.In this work,the isotope ratios of uranium in | XU Changkun ZHU Liuchao ZHAO Xinghong WANG Tongxing | 2017 | Annual Report of China Institute of Atomic Energy2017，，1： | 0 |
| 4 | Intercomparison of Attribution Analysis for Low Enriched Uranium Pellet显示文摘In order to improve the best practices of nuclear forensics,the Nuclear Forensics International Technical Working Group(ITWG)organized the 5th Collaborative Materials Exercises(CMX-5)from 2015to 2017.Worldwide,China Institute of Atomic Energy(CIAE)and other twenty laboratories participated this exercise. | WANG Tongxing LIU Guorong WANG Fan ZHANG Yan ZHU Liuchao ZHOU Hao LI Jinghuai ZHAO Xinghong CHEN Yan SHEN Yan TIAN Yuan HUANG Shenghui JIANG Xiaoyan LU Jie CHANG Li WANG Chen XU Changkun | 2017 | Annual Report of China Institute of Atomic Energy2017，，1： | 0 |
| 5 | Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer:a randomized,non-inferiority,multicenter trial显示文摘We conducted a prospective study to assess the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy (CCRT) as an alternative strategy for patients with early-stage (FIGO 2009 stage IB–IIA) cervical cancer having risk factors after surgery. The condition was assessed in terms of prognosis, adverse effects, and quality of life. This randomized trial involved nine centers across China. Eligible patients were randomized to receive adjuvant chemotherapy or CCRT after surgery. The primary end-point was progression-free survival (PFS). From December 2012 to December 2014, 337 patients were subjected to randomization. Final analysis included 329 patients, including 165 in the adjuvant chemotherapy group and 164 in the adjuvant CCRT group. The median follow-up was 72.1 months. The three-year PFS rates were both 91.9%, and the five-year OS was 90.6% versus 90.0% in adjuvant chemotherapy and CCRT groups, respectively. No significant differences were observed in the PFS or OS between groups. The adjusted HR for PFS was 0.854 (95% confidence interval 0.415–1.757;P = 0.667) favoring adjuvant chemotherapy, excluding the predefined non-inferiority boundary of 1.9. The chemotherapy group showed a tendency toward good quality of life. In comparison with post-operative adjuvant CCRT, adjuvant chemotherapy treatment showed non-inferior efficacy in patients with early-stage cervical cancer having pathological risk factors. Adjuvant chemotherapy alone is a favorable alternative post-operative treatment. | Danhui Weng Huihua Xiong Changkun Zhu Xiaoyun Wan Yaxia Chen Xinyu Wang Youzhong Zhang Jie Jiang Xi Zhang Qinglei Gao Gang Chen Hui Xing Changyu Wang Kezhen Li Yaheng Chen Yuyan Mao Dongxiao Hu Zimin Pan Qingqin Chen Baoxia Cui Kun Song Cunjian Yi Guangcai Peng Xiaobing Han Ruifang An Liangsheng Fan Wei Wang Tingchuan Xiong Yile Chen Zhenzi Tang Lin Li Xingsheng Yang Xiaodong Cheng Weiguo Lu Hui Wang Beihua Kong Xing Xie Ding Ma | 2023 | Frontiers of Medicine2023，17，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员